| Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer P Schmid, S Adams, HS Rugo, A Schneeweiss, CH Barrios, H Iwata, ... New England Journal of Medicine 379 (22), 2108-2121, 2018 | 3840 | 2018 |
| Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results … P Schmid, HS Rugo, S Adams, A Schneeweiss, CH Barrios, H Iwata, ... The lancet oncology 21 (1), 44-59, 2020 | 1080 | 2020 |
| The interplay of immunotherapy and chemotherapy: harnessing potential synergies LA Emens, G Middleton Cancer immunology research 3 (5), 436-443, 2015 | 757 | 2015 |
| Breast cancer immunotherapy: facts and hopes LA Emens Clinical cancer research 24 (3), 511-520, 2018 | 733 | 2018 |
| Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study LY Dirix, I Takacs, G Jerusalem, P Nikolinakos, HT Arkenau, ... Breast cancer research and treatment 167, 671-686, 2018 | 708 | 2018 |
| Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ... JAMA oncology 5 (1), 74-82, 2019 | 706 | 2019 |
| Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape LA Emens, PA Ascierto, PK Darcy, S Demaria, AMM Eggermont, ... European journal of cancer 81, 116-129, 2017 | 573 | 2017 |
| Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2 … JPH Machiels, RT Reilly, LA Emens, AM Ercolini, RY Lei, D Weintraub, ... Cancer research 61 (9), 3689-3697, 2001 | 551 | 2001 |
| Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response AM Ercolini, BH Ladle, EA Manning, LW Pfannenstiel, TD Armstrong, ... The Journal of experimental medicine 201 (10), 1591-1602, 2005 | 477 | 2005 |
| Targeting adenosine for cancer immunotherapy RD Leone, LA Emens Journal for immunotherapy of cancer 6, 1-9, 2018 | 467 | 2018 |
| Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade LA Emens Expert review of anticancer therapy 12 (12), 1597-1611, 2012 | 465 | 2012 |
| Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood MJ Higgins, D Jelovac, E Barnathan, B Blair, S Slater, P Powers, J Zorzi, ... Clinical cancer research 18 (12), 3462-3469, 2012 | 368 | 2012 |
| PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas A Cimino-Mathews, E Thompson, JM Taube, X Ye, Y Lu, A Meeker, H Xu, ... Human pathology 47 (1), 52-63, 2016 | 361 | 2016 |
| Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) LA Emens, FS Braiteh, P Cassier, JP Delord, JP Eder, M Fasso, Y Xiao, ... Cancer Research 75 (15_Supplement), 2859-2859, 2015 | 335* | 2015 |
| Antagonists of PD-1 and PD-L1 in cancer treatment EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian Seminars in oncology 42 (4), 587-600, 2015 | 329 | 2015 |
| First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis LA Emens, S Adams, CH Barrios, V Diéras, H Iwata, S Loi, HS Rugo, ... Annals of Oncology 32 (8), 983-993, 2021 | 304 | 2021 |
| Chemoimmunotherapy: reengineering tumor immunity G Chen, LA Emens Cancer Immunology, Immunotherapy 62, 203-216, 2013 | 279 | 2013 |
| Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment PA Philip, M Mooney, D Jaffe, G Eckhardt, M Moore, N Meropol, L Emens, ... Journal of Clinical Oncology 27 (33), 5660-5669, 2009 | 275 | 2009 |
| Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre … LA Emens, FJ Esteva, M Beresford, C Saura, M De Laurentiis, SB Kim, ... The lancet oncology 21 (10), 1283-1295, 2020 | 259 | 2020 |
| Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor–secreting breast tumor vaccine: a chemotherapy … LA Emens, JM Asquith, JM Leatherman, BJ Kobrin, S Petrik, M Laiko, ... Journal of Clinical Oncology 27 (35), 5911-5918, 2009 | 258 | 2009 |
Elizabeth JaffeeJohns Hopkins University School of Medicine在 jhmi.edu 的电子邮件经过验证
